427 related articles for article (PubMed ID: 32074275)
21. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.
Arlin ZA; Feldman EJ; Finger LR; Ahmed T; Mittelman A; Cook P; Puccio C; Baskind P; Arnold P; Razis ED
Leukemia; 1991 Aug; 5(8):712-4. PubMed ID: 1886423
[TBL] [Abstract][Full Text] [Related]
22. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
[TBL] [Abstract][Full Text] [Related]
23. Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia.
Canaani J; Nagar M; Heering G; Gefen C; Yerushalmi R; Shem-Tov N; Volchek Y; Merkel D; Avigdor A; Shimoni A; Amariglio N; Rechavi G; Nagler A
Oncotarget; 2020 Jun; 11(23):2233-2245. PubMed ID: 32577167
[TBL] [Abstract][Full Text] [Related]
24. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
Zhou JH; Lin HQ; Shen Q; Hu LN; Li GQ; Sun XF; Zhang XY
Curr Med Sci; 2018 Feb; 38(1):51-57. PubMed ID: 30074151
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
Ikezoe T; Ando K; Onozawa M; Yamane T; Hosono N; Morita Y; Kiguchi T; Iwasaki H; Miyamoto T; Matsubara K; Sugimoto S; Miyazaki Y; Kizaki M; Akashi K
Cancer Sci; 2022 Dec; 113(12):4258-4266. PubMed ID: 35689544
[TBL] [Abstract][Full Text] [Related]
27. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
[TBL] [Abstract][Full Text] [Related]
29. High-dose mitoxantrone in acute leukaemia: New York Medical College experience.
Feldman EJ
Eur J Cancer Care (Engl); 1997 Dec; 6(4 Suppl):27-32. PubMed ID: 9460340
[TBL] [Abstract][Full Text] [Related]
30. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
31. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
Mantovani L; Hasenclever D; Krahl R; Pönisch W; Herold M; Pasold R; Fiedler F; Dölken G; Kämpfe D; Schmoll HJ; Súbert R; Kubel M; Niederwieser D; Helbig W;
Leuk Lymphoma; 2002 Feb; 43(2):265-74. PubMed ID: 11999557
[TBL] [Abstract][Full Text] [Related]
32. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
33. Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Altman JK; Zuckerman T; Koprivnikar J; McCloskey J; Kota V; Keng M; Frankfurt O; Abaza Y; Bixby DL; Emadi A; Burch M; Bhatnagar B; Luger SM; Percival ME; Wolach O; Craig M; Ganzel C; Roboz G; Levi I; Gourevitch A; Flaishon L; Tessler S; Blumberg C; Gengrinovitch S; Ben Yakar R; Rowe JM
Blood Adv; 2023 Dec; 7(24):7494-7500. PubMed ID: 37903324
[TBL] [Abstract][Full Text] [Related]
34. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
36. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
37. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
[TBL] [Abstract][Full Text] [Related]
38. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
39. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
Miyamoto T; Nagafuji K; Fujisaki T; Uchida N; Matsue K; Henzan H; Ogawa R; Takase K; Aoki T; Hidaka M; Teshima T; Taniguchi S; Akashi K; Harada M;
Int J Hematol; 2018 Apr; 107(4):468-477. PubMed ID: 29243031
[TBL] [Abstract][Full Text] [Related]
40. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
